| Up Approx. 41%, Low Float Nasdaq Profile (ENTO) Impresses Early Monday
March 3rd Greetings, Friend!
(Nasdaq: ENTO) is making moves early Monday. Watch out.
ENTO, currently up approx. 41%, is reaching chart levels it hasn't sniffed since early January 2025.
Why? In part it could be due to the size of ENTO's float.
Yahoo Finance reports 4.69Mn shares in its float. Because of this little number, volatility potential could be significant on any given day.
(Nasdaq: ENTO) continues to hold the top spot on my watchlist this morning. When another update is available, I'll get it out quickly. -----
Entero Therapeutics, Inc. (Nasdaq: ENTO) has captured my attention as a compelling breakout idea.
This clinical-stage company is pioneering non-systemic treatments for various GI conditions, leveraging a trifecta of proprietary technologies.
Cutting-Edge Pipeline
Latiglutenase: A groundbreaking oral biotherapeutic poised to enter Phase 3 trials, targeting celiac disease by enhancing gluten digestion and symptom reduction.
Capeserod: This selective 5-HT4 receptor partial agonist is under development for multiple GI disorders, with a focus on gastroparesis.
Adrulipase: An innovative recombinant lipase designed to improve fat and nutrient digestion in patients with exocrine pancreatic insufficiency, particularly those affected by cystic fibrosis and chronic pancreatitis.
Additionally, Entero is advancing niclosamide-based therapies for ulcerative proctitis and immune checkpoint inhibitor-associated colitis.
Learn more about the company here.
Market Dynamics
ENTO's can be characterized as a low float idea with approximately 4.69Mn shares, as reported by Yahoo Finance.
This limited availability of tradable shares contributes to heightened volatility potential.
For instance, ENTO experienced a remarkable 92% surge from $.48 to $.926 between December 5-9, 2024.
While past performance doesn't guarantee future results, ENTO's low float structure and innovative pipeline make it an intriguing Nasdaq profile to monitor. -----
Coverage is initiated on Entero Therapeutics, Inc. (Nasdaq: ENTO).
Timely updates will be provided. Keep your eyes peeled.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Thousand Sun Media LLC has not been compensated for the March 2nd and 3rd, 2025's profile on (ENTO:US). Neither Thousand Sun Media LLC or its member own shares of (ENTO:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ | 
No comments:
Post a Comment